LCG
KYNB

Lisanti Capital Growth’s Kyntra Bio KYNB Stock Holding History

Lisanti Capital Growth’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,137
Closed -$1.78M – 136
2018
Q2 		$1.78M Buy
+1,137
New +$1.48M 0.68% 62
2018
Q1 		– Sell
-474
Closed -$562K – 120
2017
Q4 		$562K Buy
474
+224
+90% +$281K 0.32% 101
2017
Q3 		$336K Buy
+250
New +$263K 0.21% 105
2016
Q1 		– Sell
-1,427
Closed -$1.09M – 100
2015
Q4 		$1.09M Buy
1,427
+35
+3% +$23.2K 1.14% 42
2015
Q3 		$763K Buy
+1,392
New +$843K 0.69% 64

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Lisanti Capital Growth's KYNB Position: Q3 2018 in Review

Lisanti Capital Growth sold out of Kyntra Bio (KYNB) in Q3 2018, closing a stake of 1,137 shares — an estimated $1.78M sold.

Lisanti Capital Growth first reported a position in KYNB in Q3 2015 and held it in 5 quarters. The position peaked at $1.78M in Q2 2018. 187 funds tracked by Wall St. Rank hold KYNB as of Q3 2018.

  • Lisanti Capital Growth reported no remaining Kyntra Bio position as of Q3 2018 after selling out during the quarter.
  • Lisanti Capital Growth sold 1,137 Kyntra Bio shares in Q3 2018, an estimated $1.78M.
  • Lisanti Capital Growth first reported a position in Kyntra Bio in Q3 2015 and held it in 5 quarters.
  • Lisanti Capital Growth's Kyntra Bio position peaked at $1.78M in Q2 2018.
  • 187 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2018.

Based on Lisanti Capital Growth's 13F filing for Q3 2018, filed 5 Nov 2018.